Genmab A/S announced new results from the Phase 1b/2 EPCORE®? NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible forautologous stem cell transplantation (ASCT). Results demonstrated an overall response rate (ORR) of 87%, a complete response (CR) rate of 65% and a partial response (PR) of 23%.
Use of epcoritamab + R-ICE in patients with R/R DLBCL eligible for ASCT is not approved and the safety and efficacy of epcoritamab for use as a combination therapy in DLBCL have not been established. DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men. DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell.
For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets. The most common severe abnormal Laboratory test results include decreased white blood cell and decreased red blood cells.
The most common severe abnormal lab test results include decreased white bloodcells and decreased red blood cells.
